Background Ruxolitinib is a novel oral Janus kinase inhibitor that is used for treatment of
myeloproliferative diseases. It exhibits potent anti-inflammatory and immunosuppressive …

Cryptococcus neoformans (CN) is an encapsulated yeast that is found worldwide. It causes
self‐limiting infections in immunocompetent hosts; however, infections due to CN could be …

Background Ruxolitinib is a highly potent janus kinase inhibitor that places its users at risk
for various bacterial infections and viral reactivation. However new reports are also …

We report a case of Cryptococcus neoformans pneumonia in a patient taking ruxolitinib, a
janus kinase 1, 2 inhibitor approved for the treatment of myelofibrosis. We hypothesize that …

Ruxolitinib, a selective inhibitor of Janus kinases, is a standard treatment for
intermediate/high-risk myelofibrosis (MF) but is associated with a predisposition to …

Background: Primary myelofibrosis is a chronic myeloproliferative neoplasm that may cause
debilitating symptoms, which can be improved with the use of Ruxolitinib, a Janus kinase 2 …

Ruxolitinib, a Janus kinase inhibitor, improves symptoms in patients with myelofibrosis.
However, its association with the development of opportunistic infections has been a …

We present the case of a 79-year-old man who showed multiple pulmonary nodules on
chest computed tomography (CT) after being treated for 6 months with ruxolitinib, an …

Ruxolitinib is a novel therapeutic agent which is being used in the treatment of myelofibrosis.
In the literature, there are reports of opportunistic infections along with tuberculosis during …

Ruxolitinib is a novel inhibitor of the Janus kinase (JAK) pathway that has become available
for the treatment of myelofibrosis. There are increasing reports of opportunistic infections …